Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Benign prostatic hyperplasia. Part 1--diagnosis.

Literature DB >> 18202067

Benign prostatic hyperplasia. Part 1--diagnosis.

Timothy J Wilt¹, James N'Dow.

Abstract

Entities: Disease

Mesh：

Year: 2008 PMID： 18202067 PMCID： PMC2206313 DOI： 10.1136/bmj.39421.685023.AE

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

21 in total

1. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

Authors: Werner Schäfer; Paul Abrams; Limin Liao; Anders Mattiasson; Francesco Pesce; Anders Spangberg; Arthur M Sterling; Norman R Zinner; Philip van Kerrebroeck
Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696

2. Counting the cost of treating benign prostatic hyperplasia.

Authors: C L Foley; C Taylor; R S Kirby
Journal: BJU Int Date: 2004-02 Impact factor: 5.588

3. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors: M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal: J Urol Date: 1992-11 Impact factor: 7.450

4. Adverse effects of medications on urinary symptoms and flow rate: a community-based study.

Authors: L Su; H A Guess; C J Girman; S J Jacobsen; J E Oesterling; L A Panser; M M Lieber
Journal: J Clin Epidemiol Date: 1996-04 Impact factor: 6.437

5. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men.

Authors: Elizabeth A Platz; Ellen Smit; Gary C Curhan; Leroy M Nyberg; Edward Giovannucci
Journal: Urology Date: 2002-06 Impact factor: 2.649

6. High prevalence of benign prostatic hypertrophy in the community.

Authors: W M Garraway; G N Collins; R J Lee
Journal: Lancet Date: 1991-08-24 Impact factor: 79.321

7. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?

Authors: C T Brown; E O'Flynn; J Van Der Meulen; S Newman; A R Mundy; M Emberton
Journal: BJU Int Date: 2003-01 Impact factor: 5.588

8. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors: John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal: N Engl J Med Date: 2003-12-18 Impact factor: 91.245

9. The development of human benign prostatic hyperplasia with age.

Authors: S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal: J Urol Date: 1984-09 Impact factor: 7.450

10. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.

Authors: J H Wasson; D J Reda; R C Bruskewitz; J Elinson; A M Keller; W G Henderson
Journal: N Engl J Med Date: 1995-01-12 Impact factor: 91.245

5 in total

Benign prostatic hyperplasia. Part 1--diagnosis.

1. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

2. Counting the cost of treating benign prostatic hyperplasia.

3. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

4. Adverse effects of medications on urinary symptoms and flow rate: a community-based study.

5. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men.

6. High prevalence of benign prostatic hypertrophy in the community.

7. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?

8. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

9. The development of human benign prostatic hyperplasia with age.

10. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.

1. Benign prostatic hyperplasia: The term BPH is misused.

2. Benign prostatic hyperplasia: You have to put your finger in.

Review 3. Benign prostatic hyperplasia. Part 2--management.

4. Measurement of tamsulosin in human serum by liquid chromatography-tandem mass spectrometry.

5. [Quality of care indicators for benign prostatic hyperplasia. A qualitative study].